List of Excipients in Branded Drug GOOD SENSE NICOTINE

« Back to Dashboard

Generic Drugs Containing GOOD SENSE NICOTINE

Company	Ingredient	NDC	Excipient
L Perrigo Company	nicotine polacrilex	0113-0029	ACESULFAME POTASSIUM
L Perrigo Company	nicotine polacrilex	0113-0029	CALCIUM CARBONATE
L Perrigo Company	nicotine polacrilex	0113-0029	CARNAUBA WAX
L Perrigo Company	nicotine polacrilex	0113-0029	POLACRILIN
L Perrigo Company	nicotine polacrilex	0113-0029	SODIUM BICARBONATE
L Perrigo Company	nicotine polacrilex	0113-0029	SODIUM CARBONATE

What are the Most Frequently-Used Excipients in GOOD SENSE NICOTINE?

# Of NDCs	Excipient
8	ACACIA
26	ACESULFAME POTASSIUM
1	ALGIN
6	ASPARTAME
2	BENZALDEHYDE
16	CALCIUM CARBONATE

Good Sense Nicotine Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Good Sense Nicotine is a private-label nicotine-replacement therapy brand positioned around low-cost smoking-cessation products. Its commercial value depends less on novel active-ingredient protection than on dosage-form execution, flavor performance, supply reliability, retail distribution, and compliance with FDA over-the-counter requirements. The principal opportunities are premium lozenges, differentiated gum textures, pediatric-resistant packaging, nicotine pouch-adjacent formats, and lower-cost products for large retail and public-health channels.

What is Good Sense Nicotine?

Good Sense Nicotine is a consumer nicotine-replacement product line associated with nicotine polacrilex gum and other nicotine-cessation formats sold through value-oriented retail channels. The exact excipient composition depends on the dosage form, strength, flavor, manufacturer, and National Drug Code.

Product characteristic	Commercial relevance
Active ingredient	Nicotine, commonly delivered as nicotine polacrilex
Primary use	Temporary aid to stop smoking
FDA pathway	OTC nicotine-replacement therapy
Typical dosage forms	Chewing gum, lozenge, and potentially transdermal products under private-label or retail-brand arrangements
Core strengths	Low price, broad retail access, established consumer category
Main vulnerabilities	Commodity positioning, limited differentiation, taste complaints, retail substitution, and dependence on contract manufacturing

Nicotine replacement therapy products are regulated under FDA OTC requirements and nicotine-cessation labeling rules. The active ingredient is not generally protected by a single brand-specific composition patent. The commercially relevant assets are formulation know-how, manufacturing controls, packaging, trademarks, retail contracts, and regulatory dossiers.[1]

What excipients are used in Good Sense Nicotine products?

The excipient system depends on whether the product is gum, lozenge, or patch. Public product labels commonly identify inactive ingredients, but the brand name alone does not establish one uniform composition.

Nicotine gum excipient strategy

Nicotine polacrilex gum requires a chewable matrix that releases nicotine gradually when the user chews and rests the gum against the cheek. Typical excipient categories include:

Excipient category	Functional role
Gum base	Provides chewability, elasticity, and controlled nicotine release
Sweeteners	Improve palatability and support repeated use
Polyols such as sorbitol	Bulk sweetening and moisture control
Sodium carbonate or bicarbonate	Raises local pH and improves nicotine release
Humectants such as glycerin	Controls texture and prevents excessive brittleness
Flavor systems	Mask nicotine bitterness and improve adherence
Waxes or softeners	Adjust chew profile and processing behavior
Anticaking or processing aids	Improve manufacturing consistency

The most important formulation variable is pH control. Nicotine is a weak base, and an alkaline microenvironment can increase the fraction of un-ionized nicotine available for buccal absorption. Excess alkalinity, however, can increase irritation and worsen taste. The formulation therefore has to balance nicotine release, mouthfeel, salivary compatibility, and user tolerability.

Gum base selection also affects the perceived quality of the product. A low-cost formulation may release nicotine adequately but become hard, sticky, crumbly, or excessively bitter during use. These defects can reduce treatment persistence even when the product meets release specifications.

Nicotine lozenge excipient strategy

Nicotine lozenges typically use a compressed or molded matrix. Common excipient functions include:

• Mannitol or other polyols for bulk and cooling sensation
• Sodium carbonate or bicarbonate for pH adjustment
• Flavoring agents for nicotine masking
• High-intensity sweeteners for taste correction
• Binders for mechanical strength
• Lubricants to support tablet compression
• Disintegrant or matrix-control components where appropriate

Lozenge formulation is more sensitive to dissolution time than gum. A product that dissolves too quickly can increase throat irritation, hiccups, nausea, and swallowed nicotine. A product that dissolves too slowly can create poor adherence and low consumer satisfaction.

Mannitol is commercially attractive because it provides a cooling mouthfeel and relatively low hygroscopicity. Its cost is generally higher than basic sugar excipients, but the sensory benefit can support a premium price. Sucralose, acesulfame potassium, mint flavors, and cooling agents can reduce bitterness, although flavor systems must be evaluated for stability and interaction with nicotine.

Transdermal patch considerations

If Good Sense Nicotine is sold in a patch format under a related private-label arrangement, the excipient strategy changes materially. The product would rely on:

• Adhesive polymer
• Backing layer
• Release liner
• Permeation-control components
• Solvent or plasticizer system
• Printing inks and packaging materials

Patch performance depends on nicotine flux, adhesion through perspiration and movement, skin irritation, liner removal, and residual nicotine management. Patch manufacturing is more equipment-intensive than gum or lozenges and creates higher technical barriers for new entrants.

What FDA regulatory status applies to Good Sense Nicotine?

Nicotine-replacement products are generally marketed as OTC smoking-cessation products under FDA requirements applicable to nicotine gum, lozenges, and transdermal systems. Labeling must state the active ingredient, purpose, warnings, directions, and age-related restrictions consistent with the applicable FDA framework.[1][2]

Good Sense Nicotine products are not conventional prescription drugs requiring an individual new drug application for each retail label when marketed under an established OTC pathway. The regulatory burden remains significant because the manufacturer must control:

• Active-ingredient identity and assay
• Content uniformity
• Dissolution or release performance
• Nicotine degradation products
• Microbial quality where applicable
• Packaging integrity
• Stability
• Tamper evidence and child-resistant packaging requirements
• Label compliance and post-market reporting

The exact regulatory status must be assessed at the NDC and dosage-form level. A brand-level conclusion is not sufficient because different Good Sense Nicotine products may be supplied by different manufacturers.

What Orange Book status and patent protection apply?

Orange Book listing

Good Sense Nicotine products marketed through the OTC monograph system generally should not be analyzed as Orange Book-protected prescription products. The Orange Book primarily identifies approved prescription drug products and certain approved nonprescription products with specific application-based approval histories.[3]

The key commercial protections for a private-label nicotine product are therefore usually:

1. Trademark rights in the Good Sense name.
2. Retail distribution agreements.
3. Contract-manufacturing arrangements.
4. Product specifications and quality systems.
5. Formulation and process know-how.
6. Packaging and consumer-recognition assets.

Patent estate

No brand-specific patent estate can be inferred from the Good Sense name alone. Nicotine gum and lozenge technology has been commercially available for decades, and broad claims covering nicotine replacement in these dosage forms are likely to face substantial prior-art pressure.

Potentially protectable subject matter includes:

• Improved nicotine release profiles
• Reduced-bitter or taste-masked formulations
• Specific gum-base compositions
• Long-dissolving lozenge matrices
• Abuse-deterrent or misuse-limiting systems
• Improved moisture-barrier packaging
• Child-resistant dispensing systems
• Combination products
• New flavors with defined sensory or stability performance
• Manufacturing processes that improve content uniformity

The practical value of such patents depends on claim breadth, freedom-to-operate analysis, and whether the product can be designed around the claims. For a value private-label brand, trade secrets and supply-chain control may produce more commercial value than an expensive patent program.

How strong is the Good Sense Nicotine patent estate?

The patent position is likely weak at the brand level and moderate only where the underlying supplier owns formulation or manufacturing rights. Good Sense Nicotine is primarily a brand and channel asset rather than a differentiated innovator product.

Asset type	Likely strategic strength
Basic nicotine gum composition	Low to moderate
Basic nicotine lozenge composition	Low to moderate
Nicotine polacrilex active ingredient	Low as a product differentiator
Taste-masking technology	Moderate if supported by enforceable claims
Release-control technology	Moderate
Retail trademark	Moderate to strong within the relevant channel
Contract-manufacturing specification	Moderate but confidential
Packaging innovation	Moderate
Manufacturing know-how	Moderate to strong if difficult to replicate

Paragraph IV litigation is unlikely to be the principal competitive issue for a monograph-based OTC nicotine product. Competitors can usually enter by complying with the same regulatory requirements and avoiding any enforceable formulation or process claims. The more relevant risks are supplier switching, retail delisting, product-quality failures, and private-label price competition.

What excipient opportunities exist for Good Sense Nicotine?

Premium taste masking

Nicotine has a strong bitter and irritating profile. A better flavor architecture could support a premium version without changing the active ingredient. Potential approaches include:

• Layered mint systems
• Cooling agents with controlled intensity
• Sweetener combinations
• Encapsulated or microenvironmental taste-masking systems
• Reduced aftertaste
• Lower oral irritation

Any taste-masking strategy must preserve nicotine release and avoid increasing swallowed nicotine exposure.

Improved gum texture

A higher-performance gum could target defects associated with low-cost NRT products:

• Excessive hardness
• Loss of elasticity during chewing
• Stickiness
• Crumbling
• Poor flavor persistence

A differentiated gum base, controlled plasticizer ratio, or improved moisture barrier could create a defensible product specification. The opportunity is strongest in pharmacies and cessation programs where adherence and repeat use matter more than the lowest unit price.

Fast-dissolving and extended-use lozenges

Two distinct market positions are available. Fast-dissolving lozenges can appeal to consumers seeking convenience, while extended-use lozenges may provide a smoother nicotine profile and less frequent dosing. Each requires careful control of dissolution, local pH, irritation, and nicotine delivery.

Packaging and adherence systems

Packaging is an underused opportunity in OTC nicotine replacement. Potential products include:

• Calendarized blister packs
• Dose-tracking cartons
• Child-resistant unit-dose packaging
• Moisture-protective blister systems
• Travel packs
• Combined starter and maintenance kits

Packaging can create differentiation without changing the active formulation. It can also reduce accidental exposure and improve dosing compliance.

What commercial opportunities exist for Good Sense Nicotine?

Value retail expansion

The brand is well suited to mass retail, warehouse clubs, dollar stores, online marketplaces, and employer-sponsored cessation programs. The central commercial advantage is a lower price than leading branded NRT products.

Public-sector and employer contracts

Large-volume procurement can support sales through:

• Medicaid-related cessation programs
• State tobacco-control initiatives
• Employer wellness programs
• Health-plan smoking-cessation benefits
• Correctional and institutional healthcare
• Community health centers

These channels prioritize dependable supply, regulatory compliance, shelf life, and total delivered cost.

Portfolio architecture

A stronger Good Sense portfolio could include:

Product tier	Positioning
Value gum	Lowest-cost cessation option
Premium gum	Better texture and flavor persistence
Value lozenge	Broad retail accessibility
Premium lozenge	Improved taste and controlled dissolution
Starter kit	Behavioral support and initial dosing
Maintenance pack	Lower-cost recurring purchase
Combination pack	Patch plus gum or lozenge, where permitted and properly labeled

Combination NRT has clinical and commercial relevance, but labeling, promotional claims, and pack configuration must remain consistent with FDA requirements and applicable evidence.

International and geographic opportunities

The strongest geographic opportunities are markets where smoking prevalence remains high, OTC access is established, and branded NRT carries a material price premium. Geographic expansion requires separate review of:

• Local nicotine classification
• Excipient permissions
• Flavor restrictions
• Packaging rules
• Advertising limitations
• Pharmacovigilance obligations
• Import and serialization requirements

A formulation optimized for U.S. OTC distribution may require changes in excipient selection, labeling, or package size in other jurisdictions.

What manufacturing and IP barriers affect market entry?

The active ingredient is not the main barrier. The principal barriers are:

1. Consistent nicotine assay and content uniformity.
2. Control of release from gum or lozenge matrices.
3. Flavor and stability performance.
4. Specialized gum or lozenge equipment.
5. Low-moisture packaging.
6. FDA-compliant quality systems.
7. Reliable nicotine-polacrilex supply.
8. Retail qualification and vendor approval.
9. Protection against contamination and mix-ups.
10. Commercial-scale validation.

Gum manufacturing is particularly dependent on process control because mixing, extrusion, cutting, coating, and packaging can affect dose uniformity and texture. Lozenge production has different risks, including compression defects, capping, sticking, dissolution variability, and flavor migration.

How does Good Sense Nicotine compare with leading nicotine-replacement brands?

Factor	Good Sense Nicotine	Leading branded NRT
Price	Usually value-oriented	Higher
Brand recognition	Retail or private-label recognition	Strong national recognition
Patent differentiation	Limited or supplier-dependent	Often based on legacy know-how and branding
Retail access	Strong where private-label distribution is established	Broad
Flavor and dosage breadth	Depends on supplier	Typically broader
Consumer loyalty	More price-sensitive	More brand-sensitive
Commercial moat	Distribution and cost	Brand, evidence, distribution, and product breadth
Innovation potential	High through reformulation and packaging	Higher resources but greater legacy complexity

Key Takeaways

• Good Sense Nicotine is primarily a value-oriented OTC nicotine-replacement brand.
• The relevant excipients differ materially between gum, lozenge, and patch products.
• pH control, flavor masking, gum texture, dissolution, and moisture protection drive product performance.
• The brand is unlikely to depend on a broad, standalone patent estate.
• Trademark rights, retail placement, contract manufacturing, and formulation know-how are more important commercial assets.
• The strongest opportunities are premium taste-masked products, better gum texture, adherence-oriented packaging, public-sector supply, and expanded value distribution.
• Paragraph IV litigation and Orange Book exclusivity are generally less relevant than OTC compliance, supplier control, and freedom to operate.
• Manufacturing consistency is a greater entry barrier than the nicotine active ingredient itself.

FAQs

Can Good Sense Nicotine use the same excipients in gum and lozenges?

No. Gum requires a chewable elastomeric base, while lozenges require a compressed or molded matrix with controlled dissolution. Some sweeteners, buffers, and flavors may overlap, but the functional excipient systems are different.

Is nicotine polacrilex protected by a current Good Sense-specific patent?

The brand name alone does not establish a Good Sense-specific patent. Any relevant protection would need to be tied to a particular formulation, manufacturing process, packaging system, or supplier-owned technology.

Can a competitor launch a lower-cost nicotine gum?

Yes, if it meets the applicable FDA requirements, uses compliant labeling, and avoids enforceable formulation, process, trademark, and packaging rights. Cost advantages would likely come from scale, excipient procurement, manufacturing yield, and retail logistics.

Which excipient has the greatest effect on nicotine release?

The buffering system often has a major effect because local pH influences nicotine availability for buccal absorption. Gum-base composition, moisture, particle distribution, and matrix structure also affect release.

Is Good Sense Nicotine suitable for a premium reformulation strategy?

Yes. A premium version could focus on flavor persistence, reduced bitterness, improved gum texture, controlled lozenge dissolution, unit-dose packaging, and adherence support without requiring a new active ingredient.

References

1. U.S. Food and Drug Administration. (2022). Nicotine replacement therapy products: Drug facts and regulatory requirements. FDA.

2. U.S. Food and Drug Administration. (2024). Smoking cessation products and nicotine replacement therapy. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2024). DailyMed: Nicotine polacrilex gum and lozenge labeling. National Library of Medicine.